{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:43:21Z","timestamp":1790959401609,"version":"4.1.0"},"reference-count":91,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["P32762-B"],"award-info":[{"award-number":["P32762-B"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chimeric antigen receptor (CAR) T-cells (CAR T-cells) are a promising therapeutic approach in treating hematological malignancies. CAR T-cells represent engineered autologous T-cells, expressing a synthetic CAR, targeting tumor-associated antigens (TAAs) independent of major histocompatibility complex (MHC) presentation. The most common target is CD19 on B-cells, predominantly used for the treatment of lymphoma and acute lymphocytic leukemia (ALL), leading to approval of five different CAR T-cell therapies for clinical application. Despite encouraging clinical results, treatment of other hematological malignancies such as acute myeloid leukemia (AML) remains difficult. In this review, we focus especially on CAR T-cell application in different hematological malignancies as well as strategies for overcoming CAR T-cell dysfunction and increasing their efficacy.<\/jats:p>","DOI":"10.3390\/ijms22168996","type":"journal-article","created":{"date-parts":[[2021,8,22]],"date-time":"2021-08-22T21:47:52Z","timestamp":1629668872000},"page":"8996","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["CAR T-Cell Therapy in Hematological Malignancies"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8331-0922","authenticated-orcid":false,"given":"Theresa","family":"Haslauer","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria"},{"name":"Department of Biosciences, Paris Lodron University of Salzburg, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-3694","authenticated-orcid":false,"given":"Richard","family":"Greil","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9775-185X","authenticated-orcid":false,"given":"Nadja","family":"Zaborsky","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-2191","authenticated-orcid":false,"given":"Roland","family":"Geisberger","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research (SCRI-LIMCR), Cancer Cluster Salzburg, Paracelsus Medical University, 5020 Salzburg, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1600-065X.2011.01007.x","article-title":"Shifting the equilibrium in cancer immunoediting: From tumor tolerance to eradication","volume":"241","author":"Quezada","year":"2011","journal-title":"Immunol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/2326-6066.CIR-15-0190","article-title":"T-cell\u2013based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition","volume":"3","author":"Houot","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2174\/1389201019666180418095526","article-title":"CAR T-cell Therapy: A New Era in Cancer Immunotherapy","volume":"19","author":"Miliotou","year":"2018","journal-title":"Curr. Pharm. Biotechnol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","first-page":"e3486","article-title":"Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer","volume":"10","author":"Tariq","year":"2018","journal-title":"Cureus"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/cgt.2015.5","article-title":"Performance-enhancing drugs: Design and production of redirected chimeric antigen receptor (CAR) T cells","volume":"22","author":"Levine","year":"2015","journal-title":"Cancer Gene Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/14712598.2018.1384810","article-title":"Treating hematological malignancies with cell therapy: Where are we now?","volume":"18","author":"Landoni","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_10","unstructured":"FDA (2021, June 10). Anna Kwilas, PhD, Chair of the Review Committee, OTAT\/DCGT. Summary Basis for Regulatory Action\u2014Abecma, 26 March 2021, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/abecma-idecabtagene-vicleucel."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","article-title":"CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success","volume":"35","author":"Fiorenza","year":"2021","journal-title":"BioDrugs"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.3389\/fimmu.2019.02250","article-title":"Engineered T Cell Therapy for Cancer in the Clinic","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_13","unstructured":"NIH U.S. National library of Medicine (2021, May 27). National library of Medicine. \u201cClinicalTrials.gov,\u201d NIH U.S. National Library of Medicine, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?term=CAR&cond=Multiple+Myeloma&Search=Apply&recrs=b&recrs=a&recrs=f&recrs=d&recrs=e&age_v=&gndr=&type=&rslt=."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.hoc.2009.04.009","article-title":"Acute lymphoblastic leukemia","volume":"23","author":"Onciu","year":"2009","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3322\/caac.21219","article-title":"Childhood and adolescent cancer statistics, 2014","volume":"64","author":"Ward","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"ref_16","first-page":"3739","article-title":"Oncogenetics and minimal residual disease are independent outcome predictors in adult pa-tients with acute lymphoblastic leukemia","volume":"123","author":"Beldjord","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_17","first-page":"166","article-title":"Treatment of relapsed\/refractory acute lym-pho-blastic leukemia","volume":"17","author":"Paul","year":"2019","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"key":"ref_19","unstructured":"FDA (2021, June 10). Xiaobin Victor Lu, Ph.D., Chair of the Review Committee, Summary Basis for Regulatory Action\u2014Kymriah, 30 August 2017, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/kymriah-tisagenlecleucel."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_23","unstructured":"NIH U.S. National library of Medicine (2021, June 04). \u201cClinicalTrials.gov,\u201d NIH U.S. National Library of Medicine, Available online: https:\/\/clinicaltrials.gov\/ct2\/results?term=CAR+T+cell+therapy&cond=Acute+Lymphoid+Leukemia&Search=Clear&age_v=&gndr=&type=&rslt=."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cancergen.2013.01.003","article-title":"Chronic lymphocytic leukemia: A clinical and molecular heterogenous disease","volume":"206","year":"2013","journal-title":"Cancer Genet."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_26","first-page":"2745","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e122627","DOI":"10.1172\/jci.insight.122627","article-title":"Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for re-lapsed\/refractory CLL","volume":"4","author":"Geyer","year":"2019","journal-title":"JCI Insight"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.19.03237","article-title":"Long-term outcomes from a randomized dose optimization study of chimeric antigen receptor modi-fied T cells in relapsed chronic lymphocytic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.ymthe.2018.05.018","article-title":"Autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine ana-log-based therapy","volume":"26","author":"Geyer","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_30","first-page":"1146","article-title":"Richter\u2019s transformation in chronic lymphocytic leukemia","volume":"26","author":"Jain","year":"2012","journal-title":"Oncology"},{"key":"ref_31","first-page":"1647","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"ref_34","unstructured":"FDA (2021, June 10). Michael Havert, PhD, Chair of the Review Committee, Summary Basis for Regulatory Action\u2014Yescarta, 18 October 2017, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/yescarta-axicabtagene-ciloleucel."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2147\/CMAR.S163225","article-title":"Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: Perspectives on the therapeutic potential of Axicabtagene ciloleucel","volume":"11","author":"Viardot","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lym-pho-ma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_37","unstructured":"FDA (2021, June 10). Kimberly LW Schultz, PhD, Chair of the Review Committee, Summary Basis for Regulatory Action Template\u2014Breyanzi, 5 Feburary 2021, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/breyanzi-lisocabtagene-maraleucel."},{"key":"ref_38","unstructured":"FDA (2021, June 10). Graeme Price PhD, Chair of the Review Committee, Summary Basis for Regulatory Action\u2014Tecartus, 23 July 2020, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/tecartus-brexucabtagene-autoleucel."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.clim.2014.10.002","article-title":"Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells","volume":"155","author":"Wang","year":"2014","journal-title":"Clin. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial","volume":"23","author":"Wang","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2040620719841581","DOI":"10.1177\/2040620719841581","article-title":"CAR T-cell therapy for B-cell lymphomas: Clinical trial results of available products","volume":"10","author":"Chavez","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/bjh.13889","article-title":"Chimeric Antigen Receptor (CAR) therapy for multiple myeloma","volume":"172","author":"Atanackovic","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocit.2014.11.001","article-title":"CD138-directed adoptive immunotherapy of chimeric antigen receptor (CAR)-modified T cells for multiple myeloma","volume":"2","author":"Guo","year":"2016","journal-title":"J. Cell. Immunother."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1186\/1471-2407-12-304","article-title":"Myeloid malignancies: Mutations, models and management","volume":"12","author":"Murati","year":"2012","journal-title":"BMC Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2019001239","article-title":"How I treat acute myeloid leukemia in the era of new drugs","volume":"135","author":"Dinardo","year":"2020","journal-title":"Blood"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leuke-mia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute mye-loid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML","volume":"33","author":"Haubner","year":"2018","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1089\/hum.2017.126","article-title":"CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies","volume":"28","author":"Martyniszyn","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Condomines, M., Arnason, J., Benjamin, R., Gunset, G., Plotkin, J., and Sadelain, M. (2015). Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130518"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.ymthe.2005.04.016","article-title":"A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells","volume":"12","author":"Pule","year":"2005","journal-title":"Mol. Ther."},{"key":"ref_57","first-page":"696","article-title":"CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo","volume":"119","author":"Song","year":"2012","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2326-6066.CIR-14-0186","article-title":"Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells","volume":"3","author":"Frigault","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR T cells: Current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1158\/2159-8290.CD-17-0538","article-title":"Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells","volume":"7","author":"Shum","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cellimm.2017.10.002","article-title":"Exhaustion of T lymphocytes in the tumor microenvironment: Significance and effective mechanisms","volume":"322","author":"Gholami","year":"2017","journal-title":"Cell. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"E2776","DOI":"10.1073\/pnas.1620498114","article-title":"Exhaustion-associated regulatory regions in CD8+ tumor-infiltrating T cells","volume":"114","author":"Mognol","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e1273302","DOI":"10.1080\/2162402X.2016.1273302","article-title":"CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy","volume":"6","author":"Chen","year":"2017","journal-title":"OncoImmunology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-20-1457","article-title":"CD19-specific CAR T Cells that Express a PD-1\/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1\u2013positive B-Cell Lymphoma","volume":"27","author":"Liu","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13045-021-01044-y","article-title":"CD19 CAR-T expressing PD-1\/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies","volume":"14","author":"Liang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2016-09-738245","article-title":"PD-1 blockade modulates chimeric antigen receptor (CAR)\u2013modified T cells: Refueling the CAR","volume":"129","author":"Chong","year":"2017","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2217\/imt.10.99","article-title":"Small-molecule protein kinase inhibitors and their effects on the immune system: Implications for cancer treatment","volume":"3","author":"Ott","year":"2011","journal-title":"Immunotherapy"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1056\/NEJMoa1210093","article-title":"Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations","volume":"367","author":"Flaherty","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1158\/1078-0432.CCR-16-0906","article-title":"A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma","volume":"23","author":"Deniger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-017-0227-4","article-title":"Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy","volume":"5","author":"Urak","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/mt.2011.179","article-title":"Com-bining mTor inhibitors with rapamycin-resistant T cells: A two-pronged approach to tumor elimination","volume":"19","author":"Huye","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","article-title":"Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia","volume":"127","author":"Fraietta","year":"2016","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"805629","DOI":"10.1155\/2012\/805629","article-title":"Systemic Delivery of Oncolytic Viruses: Hopes and Hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1089\/hum.2009.082","article-title":"Infection and killing of multiple myeloma by adenoviruses","volume":"21","author":"Senac","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor\u2013Modified T Cells in Solid Tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic Melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic mela-noma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jcyt.2017.03.067","article-title":"Low interleukin-2 concentration favors generation of early memory T cells over effector pheno-types during chimeric antigen receptor T-cell expansion","volume":"19","author":"Kaartinen","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"ref_86","first-page":"188","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_88","first-page":"21","article-title":"CAR T-cell therapy: Adverse events and management","volume":"10","author":"Adkins","year":"2019","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1056\/NEJMra0904569","article-title":"The tumor lysis syndrome","volume":"364","author":"Howard","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.14680","article-title":"Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy","volume":"181","author":"Mei","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s13238-017-0411-9","article-title":"Increasing the safety and efficacy of chimeric antigen receptor T cell therapy","volume":"8","author":"Li","year":"2017","journal-title":"Protein Cell"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8996\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:48:11Z","timestamp":1760165291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/16\/8996"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":91,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["ijms22168996"],"URL":"https:\/\/doi.org\/10.3390\/ijms22168996","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}